Patents by Inventor Evripidis Gavathiotis

Evripidis Gavathiotis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS FOR ORGAN AND TISSUE PRESERVATION
    Publication number: 20250134095
    Abstract: Disclosed are compositions and methods for the preservation, storage, and transport of living biological tissues, organs, and populations of isolated cells. In particular, the compositions and methods permit mammalian cells, tissues, and organs to be recovered from suitable donor animals, stored for prolonged periods, and transported to the site of recipient implantation, all without significant loss of cell viability, biological activity, and/or tissue integrity.
    Type: Application
    Filed: August 19, 2022
    Publication date: May 1, 2025
    Inventors: Evripidis Gavathiotis, Richard N. Kitsis, Gregory Tietjen, Jenna Dirito
  • BAX ACTIVATORS AND USES THEREOF IN CANCER THERAPY
    Publication number: 20250032462
    Abstract: Activators of BAX and their uses in cancer therapy are disclosed.
    Type: Application
    Filed: June 24, 2024
    Publication date: January 30, 2025
    Inventors: Evripidis Gavathiotis, Denis E. Reyna, Felix Kopp, Ulrich Steidl
  • SMALL MOLECULE BAX INHIBITORS AND USES THEREOF
    Publication number: 20250000857
    Abstract: Compounds as inhibitors of Bcl-2-associated x-protein (BAX) and pharmaceutical compositions thereof are disclosed. Also disclosed are methods of using these compounds for preserving a tissue or treating a disease or disorder in which it is desirable to inhibit BAX.
    Type: Application
    Filed: September 6, 2024
    Publication date: January 2, 2025
    Inventors: Evripidis Gavathiotis, Richard N. Kitsis
  • MITOFUSIN INHIBITORS AND USES THEREOF
    Publication number: 20240366540
    Abstract: Disclosed herein are mitofusin inhibitors which are capable of inducing mitochondrial fission, decreasing mitochondrial respiration, TCA metabolism, and inducing mitochondrial outer membrane permeabilization that leads to caspase activation and DNA damage signaling. Also disclosed are methods of treating diseases or conditions associated with imbalanced mitochondrial dynamics.
    Type: Application
    Filed: June 6, 2024
    Publication date: November 7, 2024
    Inventors: Evripidis Gavathiotis, Emmanouil Zacharioudakis
  • SMALL MOLECULE BAX INHIBITORS AND USES THEREOF
    Publication number: 20240350482
    Abstract: Compounds, compositions and method of using these compounds are disclosed for treating a disease or disorder in which it is desirable to inhibit BAX, such as a cardiovascular disease or disorder.
    Type: Application
    Filed: March 5, 2024
    Publication date: October 24, 2024
    Inventors: Evripidis Gavathiotis, Richard N. Kitsis, Thomas Peter Garner, Dulguun Amgalan, Lorrie Kirshenbaum, Felix Kopp
  • MITOFUSIN ACTIVATORS AND USES THEREOF
    Publication number: 20240335455
    Abstract: Activators of mitofusins and their uses in treatment of diseases and disorders are disclosed.
    Type: Application
    Filed: October 9, 2023
    Publication date: October 10, 2024
    Inventors: Evripidis Gavathiotis, Richard N. Kitsis, Nikolaos Biris, Emmanouil Zacharioudakis
  • BAX activators and uses thereof in cancer therapy
    Patent number: 12016845
    Abstract: Activators of BAX and their uses in cancer therapy are disclosed.
    Type: Grant
    Filed: June 7, 2022
    Date of Patent: June 25, 2024
    Assignee: Albert Einstein College of Medicine
    Inventors: Evripidis Gavathiotis, Denis E. Reyna, Felix Kopp, Ulrich Steidl
  • Small molecule BAX inhibitors and uses thereof
    Patent number: 11938128
    Abstract: Compounds, compositions and method of using these compounds are disclosed for treating a disease or disorder in which it is desirable to inhibit BAX, such as a cardiovascular disease or disorder.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: March 26, 2024
    Assignees: Albert Einstein College of Medicine, The University of Manitoba
    Inventors: Evripidis Gavathiotis, Richard N. Kitsis, Thomas P. Garner, Dulguun Amgalan, Lorrie Kirshenbaum, Felix Kopp
  • COMPOUNDS AND METHODS FOR INHIBITION OF BAX-MEDIATED CELL DEATH
    Publication number: 20240043389
    Abstract: This disclosure provides novel compounds and methods for inhibiting BAX activity and BAX-mediated apoptosis, as well as compounds and methods for treating or preventing BAX-mediated disorders.
    Type: Application
    Filed: September 1, 2021
    Publication date: February 8, 2024
    Applicant: Albert Einstein College of Medicine
    Inventor: Evripidis Gavathiotis
  • Compounds useful as chaperone-mediated autophagy modulators
    Patent number: 11834424
    Abstract: Compounds and pharmaceutically acceptable salts thereof of Formula I are disclosed. Certain compounds and salts of Formula I are active as CMA modulators. The disclosure provides pharmaceutical compositions containing a compound of Formula I.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: December 5, 2023
    Assignee: ALBERT EINSTEIN COLLEGE OF MEDICINE
    Inventors: Ana Maria Cuervo, Evripidis Gavathiotis
  • COMBINATION THERAPY USING BAX ACTIVATOR AGENT
    Publication number: 20230372307
    Abstract: A pharmaceutical combination comprising a B-cell lymphoma 2 associated X protein (BAX) activating compound an anti-apoptotic protein inhibiting compound is provided. The disclosure also provides a method of treating cancer in a subject by administering a B-cell lymphoma 2 associated X protein (BAX) activating compound in combination with an anti-apoptotic protein inhibiting compound, such as a BCL-XL, BCL-2, BFL-1. BCL-w, or MCL-1 inhibiting compound.
    Type: Application
    Filed: September 17, 2021
    Publication date: November 23, 2023
    Inventor: Evripidis Gavathiotis
  • Mitofusin activators and uses thereof
    Patent number: 11813268
    Abstract: Activators of mitofusins and their uses in treatment of diseases and disorders are disclosed.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: November 14, 2023
    Assignee: Albert Einstein College of Medicine
    Inventors: Evripidis Gavathiotis, Richard N. Kitsis, Nikolaos Biris, Emmanouil Zacharioudakis
  • Targeting dimerization of BAX to modulate BAX activity
    Patent number: 11760780
    Abstract: Methods are provided for identifying an agent that directly modulates a Bcl-2-associated x-protein (BAX) by promoting or disrupting dimerization of the BAX. Agents that directly modulate BAX by affecting dimerization are also provided.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: September 19, 2023
    Assignee: Albert Einstein College of Medicine
    Inventor: Evripidis Gavathiotis
  • INHIBITION OF BAX-MEDIATED CELL DEATH BY ELTROMBOPAG
    Publication number: 20230270721
    Abstract: This disclosure provides methods for inhibiting BAX activity and BAX-mediated apoptosis, as well as methods for treating or preventing BAX-mediated disorders, based, in part, on an unexpected discovery that eltrombopag (EO) can work as as a potent binder to the BAX trigger site and an effective direct BAX inhibitor.
    Type: Application
    Filed: April 15, 2021
    Publication date: August 31, 2023
    Inventor: Evripidis Gavathiotis
  • Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof
    Patent number: 11591324
    Abstract: Compounds, compositions and methods are provided for selectively activating chaperone-mediated autophagy (CMA), protecting cells from oxidative stress, proteotoxicity and lipotoxicity, and/or antagonizing activity of retinoic acid receptor alpha (RAR?) in subjects in need thereof.
    Type: Grant
    Filed: August 4, 2020
    Date of Patent: February 28, 2023
    Assignee: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
    Inventors: Ana Maria Cuervo, Evripidis Gavathiotis, Qisheng Xin, Bhaskar C. Das
  • BAX ACTIVATORS AND USES THEREOF IN CANCER THERAPY
    Publication number: 20220313665
    Abstract: Activators of BAX and their uses in cancer therapy are disclosed.
    Type: Application
    Filed: June 7, 2022
    Publication date: October 6, 2022
    Applicant: Albert Einstein College of Medicine
    Inventors: Evripidis Gavathiotis, Denis E. Reyna, Felix Kopp, Ulrich Steidl
  • PYRAZOL-3-ONES THAT ACTIVATE PRO-APOPTOTIC BAX
    Publication number: 20220298154
    Abstract: This application features pyrazol-3-one compounds that activate pro-apoptotic BAX. Also featured are methods of using such compounds, e.g., for the treatment or prevention of diseases, disorders, and conditions associated with deregulated apoptosis of cells (e.g., insufficient apoptosis of diseased or damaged cells or essentially the absence of apoptosis of diseased or damaged cells).
    Type: Application
    Filed: May 27, 2022
    Publication date: September 22, 2022
    Inventors: Loren D. Walensky, Evripidis Gavathiotis
  • BAX activators and uses thereof in cancer therapy
    Patent number: 11382898
    Abstract: Activators of BAX and their uses in cancer therapy are disclosed.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: July 12, 2022
    Assignee: Albert Einstein College of Medicine
    Inventors: Evripidis Gavathiotis, Denis E. Reyna, Felix Kopp, Ulrich G. Steidl
  • Pyrazol-3-ones that activate pro-apoptotic BAX
    Patent number: 11358960
    Abstract: This application features pyrazol-3-one compounds that activate pro-apoptotic BAX. Also featured are methods of using such compounds, e.g., for the treatment or prevention of diseases, disorders, and conditions associated with deregulated apoptosis of cells (e.g., insufficient apoptosis of diseased or damaged cells or essentially the absence of apoptosis of diseased or damaged cells).
    Type: Grant
    Filed: October 6, 2020
    Date of Patent: June 14, 2022
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Loren D. Walensky, Evripidis Gavathiotis
  • BENZOXAZOLE AND RELATED COMPOUNDS USEFUL AS CHAPERONE-MEDIATED AUTOPHAGY MODULATORS
    Publication number: 20210387953
    Abstract: Compounds and pharmaceutically acceptable salts thereof of Formula I are disclosed. The variables, e.g. R1-R9, X, and Y are defined herein. Certain compounds and salts of Formula I are active as CMA modulators. The disclosure provides pharmaceutical compositions containing a compound of Formula I and methods of treating disorders responsive to CMA modulation.
    Type: Application
    Filed: October 10, 2019
    Publication date: December 16, 2021
    Inventors: Ana Maria Cuervo, Evripidis Gavathiotis